RENTON HOLLINGS sold $249K of ANAB
RENTON HOLLINGS sold 5,000 shares of ANAPTYSBIO, INC (ANAB) at $49.87 ($0.25M total) on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest in size relative to ANAB's market cap, so price impact is expected to be limited.
Market read
A routine insider sale with modest dollar value; unlikely to move the stock significantly.
What to watch
Potential upcoming clinical data releases that may offset the negative perception of the insider sale.
Background
Form 4 filings disclose insider transactions and are primary sources for such events.
Ticker impact
Director Renton Hollings sold 5,000 shares of ANAB for $249,371, reducing his stake to 10,995 shares under a 10b5‑1 plan.
likely slight downward pressure as the market prices the insider sell.
A $250k sale by a director is modest but could be interpreted as a negative signal, especially given the open‑market nature of the transaction.
Market effects
Minimal impact on the biotech sector; insider sales are routine.
No broader regional effect.
Limited to ANAB shareholders.
Counterpoint
The sale could be unrelated to company fundamentals and merely portfolio rebalancing.
Key entities
- PersonRenton Hollings
Director of Anaptysbio, Inc.
- CompanyAnaptysbio, Inc.
Biotech firm developing therapies for rare diseases.
